tirzepatide gip glp 1 Tirzepatide: A Novel, Once-weekly Dual and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Tirzepatide (GLP-1 / GIP)

Novo Nordisk referenced the FDA's concerns in its lawsuit announcement on Monday, saying Hims & Hers' compounded drugs "may contain dangerous impurities or incorrect amounts of active ingredients, which can result in life-threatening immune responses"

The Metabolic Connection At Kings Community Development Global Initiative, we recognize the growing burden of hypertension as not just a cardiovascular challenge but a metabolic risk factor, a key player in the cardiovascular kidney metabolic (CKM) syndrome now emphasized in the 2025 AHA/ACC Blood Pressure Guideline

Subjects included healthy volunteers and subjects with renal or hepatic impairment, a small number of whom also had T2D

Consult with Healthcare Professionals: Make sure to consult your healthcare provider before beginning any new medication or weight loss program